CSS LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

CSS LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-500	Closed	-$122K	–	831
2024 Q2	$122K	Buy	+500	New	+$78.9K	0.01%	742
2022 Q3	–	Sell	-5,000	Closed	-$729K	–	1047
2022 Q2	$729K	Buy	+5,000	New	+$709K	0.03%	487
2022 Q1	–	Sell	-5,000	Closed	-$848K	–	1157
2021 Q4	$848K	Buy	+5,000	New	+$929K	0.03%	487

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CSS LLC's ALNY Position: Q4 2025 in Review

CSS LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 2,010 shares — an estimated $917K sold.

CSS LLC first reported a position in ALNY in Q3 2022 and held it in 4 quarters. The position peaked at $2.06M in Q3 2024. 849 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

CSS LLC reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
CSS LLC sold 2,010 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $917K.
CSS LLC first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 4 quarters.
CSS LLC's Alnylam Pharmaceuticals position peaked at $2.06M in Q3 2024.
849 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on CSS LLC's 13F filing for Q4 2025, filed 17 Feb 2026.